卡博替尼对比舒尼替尼作为中危或低危转移性肾细胞癌患者初始靶向治疗:Alliance A031203 CABOSUN试验
这项随机II期多中心试验纳入157例未经治疗的透明细胞转移性肾细胞癌中危或低危患者,按1:1随机接受卡博替尼(60 mg每日一次)或舒尼替尼(50 mg每日一次,服4周停2周)。卡博替尼较舒尼替尼显著延长中位无进展生存期(8.2个月 vs 5.6个月),并提高客观缓解率(33% vs 12%)。
要点
- 卡博替尼较舒尼替尼显著延长中位无进展生存期(8.2个月 vs 5.6个月)。
- 卡博替尼组客观缓解率为33%,舒尼替尼组为12%。
- 两组3级或4级不良事件发生率相似(67% vs 68%)。
核心结论
- 在中危或低危转移性肾细胞癌患者中,卡博替尼作为一线治疗在无进展生存期和客观缓解率方面较标准治疗舒尼替尼显示出显著临床获益。
研究设计与样本
- 随机II期多中心试验,纳入157例未经治疗的透明细胞转移性肾细胞癌患者,按1:1随机分配至卡博替尼组(n=79)或舒尼替尼组(n=78)。
主要发现
- 卡博替尼组中位无进展生存期为8.2个月,舒尼替尼组为5.6个月。
- 卡博替尼组疾病进展或死亡风险较舒尼替尼组降低34%(校正风险比0.66,95% CI 0.46至0.95,单侧P=0.012)。
- 卡博替尼组客观缓解率为33%(95% CI 23至44),舒尼替尼组为12%(95% CI 5.4至21)。
- 全因3级或4级不良事件发生率卡博替尼组为67%,舒尼替尼组为68%;其中腹泻(卡博替尼10% vs 舒尼替尼11%)、疲乏(6% vs 15%)、高血压(28% vs 22%)、掌跖红斑感觉异常综合征(8% vs 4%)、血液学不良事件(3% vs 22%)。
关键数值与推荐
- 入组标准为未经治疗的透明细胞转移性肾细胞癌、东部肿瘤协作组体能状态0至2分、符合国际转移性肾细胞癌数据库联盟中危或低危标准。
- 卡博替尼给药方案为60 mg每日一次口服;舒尼替尼为50 mg每日一次口服,服4周停2周。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Cabozantinib is an oral potent inhibitor of vascular endothelial growth factor receptor 2, MET, and AXL and is a standard second-line therapy for metastatic renal cell carcinoma (mRCC). This randomized phase II multicenter trial evaluated cabozantinib compared with sunitinib as first-line therapy in patients with mRCC. Patients and Methods Eligible patients had untreated clear cell mRCC and Eastern Cooperative Oncology Group performance status of 0 to 2 and were intermediate or poor risk per International Metastatic Renal Cell Carcinoma Database Consortium criteria. Patients were randomly assigned at a one-to-one ratio to cabozantinib (60 mg once per day) or sunitinib (50 mg once per day; 4 weeks on, 2 weeks off). Progression-free survival (PFS) was the primary end point. Objective response rate (ORR), overall survival, and safety were secondary end points. Results From July 2013 to April 2015, 157 patients were randomly assigned (cabozantinib, n = 79; sunitinib, n = 78). Compared with sunitinib, cabozantinib treatment significantly increased median PFS (8.2 v 5.6 months) and was associated with a 34% reduction in rate of progression or death (adjusted hazard ratio, 0.66; 95% CI, 0.46 to 0.95; one-sided P = .012). ORR was 33% (95% CI, 23 to 44) for cabozantinib versus 12% (95% CI, 5.4 to 21) for sunitinib. All-causality grade 3 or 4 adverse events were 67% for cabozantinib and 68% for sunitinib and included diarrhea (cabozantinib, 10% v sunitinib, 11%), fatigue (6% v 15%), hypertension (28% v 22%), palmar-plantar erythrodysesthesia (8% v 4%), and hematologic adverse events (3% v 22%). Conclusion Cabozantinib demonstrated a significant clinical benefit in PFS and ORR over standard-of-care sunitinib as first-line therapy in patients with intermediate- or poor-risk mRCC.
引用
- Choueiri TK, Halabi S, Sanford BL, et al. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. J Clin Oncol. 2016. PMID: 28199818. doi:10.1200/JCO.2016.70.7398
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。